Luciano Rossetti becomes Executive Vice President of Research and Development at Merck Serono, the biopharmaceutical division of Merck, on 21 July.
In his most recent role, Rossetti was Senior Vice President Late Stage Development at Merck Sharp & Dohme (MSD). In this position, he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas. Before joining MSD in 2006, Rossetti was an internationally recognised academic scientist for 18 years.
Belén Garijo, President and CEO at Merck Serono, said Rossetti's breadth of experience and solid track record in research and development, together with his distinct leadership profile, would be instrumental in driving the development of the company's promising pipeline forward.
Rossetti will be based in Billerica, outside Boston, Massachusetts, US, and share his time between Merck’s headquarters in Darmstadt, Germany and Billerica – one of Merck Serono’s four global R&D hubs.
